Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Men Versus Women.
Rodriguez F, Harrington RA. Rodriguez F, et al. Among authors: harrington ra. Circ Cardiovasc Interv. 2018 Aug;11(8):e007016. doi: 10.1161/CIRCINTERVENTIONS.118.007016. Circ Cardiovasc Interv. 2018. PMID: 30354789 Free article. No abstract available.
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA; INNOVATE-PCI Investigators. Welsh RC, et al. Among authors: harrington ra. Circ Cardiovasc Interv. 2012 Jun;5(3):336-46. doi: 10.1161/CIRCINTERVENTIONS.111.964197. Epub 2012 May 29. Circ Cardiovasc Interv. 2012. PMID: 22647518 Clinical Trial.
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial.
Kaul P, Tanguay JF, Newby LK, Hochman JS, Westerhout CM, Califf RM, Tricoci P, Gibson CM, Giugliano RP, Harrington RA, Van de Werf F, Armstrong PW. Kaul P, et al. Among authors: harrington ra. Am Heart J. 2013 Oct;166(4):723-8. doi: 10.1016/j.ahj.2013.07.014. Epub 2013 Sep 5. Am Heart J. 2013. PMID: 24093853 Clinical Trial.
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. White HD, et al. Among authors: harrington ra. JACC Cardiovasc Interv. 2015 Mar;8(3):424-433. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18. JACC Cardiovasc Interv. 2015. PMID: 25703887 Free article. Clinical Trial.
Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy.
Hess CN, Krucoff MW, Sheng S, Anstrom KJ, Barham WB, Gilchrist IC, Harrington RA, Jacobs AK, Mehran R, Messenger JC, Mark DB, Rao SV. Hess CN, et al. Among authors: harrington ra. Am Heart J. 2015 Aug;170(2):371-9. doi: 10.1016/j.ahj.2015.04.024. Epub 2015 May 4. Am Heart J. 2015. PMID: 26299236 Clinical Trial.
Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial.
Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith PK, Lopes RD. Harskamp RE, et al. Among authors: harrington ra. Circulation. 2016 Jan 12;133(2):131-8. doi: 10.1161/CIRCULATIONAHA.115.015549. Epub 2015 Dec 8. Circulation. 2016. PMID: 26647082 Free PMC article.
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Déry JP, Mahaffey KW, Tricoci P, White HD, Podder M, Westerhout CM, Moliterno DJ, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV. Déry JP, et al. Among authors: harrington ra. Catheter Cardiovasc Interv. 2016 Aug;88(2):163-73. doi: 10.1002/ccd.26335. Epub 2015 Dec 23. Catheter Cardiovasc Interv. 2016. PMID: 26698636 Clinical Trial.
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
O'Donoghue ML, Bhatt DL, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Deliargyris EN, Mahaffey KW, White HD, Harrington RA; CHAMPION PHOENIX Investigators. O'Donoghue ML, et al. Among authors: harrington ra. Circulation. 2016 Jan 19;133(3):248-55. doi: 10.1161/CIRCULATIONAHA.115.017300. Circulation. 2016. PMID: 26762525 Free PMC article. Clinical Trial.
751 results